{"medgen_id":"C0014761","alternate_names":["Fetal Erythroblastosis","Hemolytic Disease of the Newborn"],"keywords":[],"alternate_symbols":[],"xrefs":["{\"db\":\"SNOMED CT\",\"id\":\"387705004\",\"ref_field\":\"name\"}"],"name":"Hemolytic disease of fetus OR newborn due to isoimmunization","attribute_content":[],"type":"Disease","id":"17390"}
{"medgen_id":"C2749936","alternate_names":["INTELLECTUAL DISABILITY, MOTOR DYSFUNCTION, AND JOINT CONTRACTURES","SPASTIC PARAPLEGIA 18, AUTOSOMAL RECESSIVE"],"keywords":[],"symbol":"SPG18","alternate_symbols":["IDMDC"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"611225\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"209951\"}","{\"db\":\"OMIM\",\"id\":\"611225\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"INTELLECTUAL DISABILITY, MOTOR DYSFUNCTION, AND JOINT CONTRACTURES\"}","{\"db\":\"OMIM\",\"id\":\"611225\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPASTIC PARAPLEGIA 18, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"611605.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPASTIC PARAPLEGIA 18, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"611605.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPASTIC PARAPLEGIA 18, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"611225\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"IDMDC\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Spastic+paraplegia+18/6684\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"611225\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Spastic paraplegia 18","attribute_content":[],"type":"Disease","id":"6839"}
{"medgen_id":"C1840061","alternate_names":["Congenital coxa vara, patella aplasia and tarsal synostosis","ISCHIOCOXOPODOPATELLAR SYNDROME","ISCHIOCOXOPODOPATELLAR SYNDROME WITH OR WITHOUT PULMONARY ARTERIAL HYPERTENSION","Ischiopatellar dysplasia","PATELLA APLASIA, COXA VARA, AND TARSAL SYNOSTOSIS","Patella aplasia, coxa vara, tarsal synostosis","Scott-Taor syndrome","Small patella syndrome"],"keywords":[],"gard_id":"3030","alternate_symbols":["ICPPS","SPS"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007841\"}","{\"db\":\"OMIM\",\"id\":\"147891\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1509\"}","{\"db\":\"OMIM\",\"id\":\"601719.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ISCHIOCOXOPODOPATELLAR SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"601719.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ISCHIOCOXOPODOPATELLAR SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"601719.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ISCHIOCOXOPODOPATELLAR SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"601719.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ISCHIOCOXOPODOPATELLAR SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"147891\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ISCHIOCOXOPODOPATELLAR SYNDROME WITH OR WITHOUT PULMONARY ARTERIAL HYPERTENSION\"}","{\"db\":\"OMIM\",\"id\":\"601719.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ISCHIOCOXOPODOPATELLAR SYNDROME WITH OR WITHOUT PULMONARY ARTERIAL HYPERTENSION\"}","{\"db\":\"OMIM\",\"id\":\"601719.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ISCHIOCOXOPODOPATELLAR SYNDROME WITH OR WITHOUT PULMONARY ARTERIAL HYPERTENSION\"}","{\"db\":\"OMIM\",\"id\":\"601719.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ISCHIOCOXOPODOPATELLAR SYNDROME WITH OR WITHOUT PULMONARY ARTERIAL HYPERTENSION\"}","{\"db\":\"OMIM\",\"id\":\"601719.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ISCHIOCOXOPODOPATELLAR SYNDROME WITH OR WITHOUT PULMONARY ARTERIAL HYPERTENSION\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ischiopatellar+dysplasia/3879\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Ischiopatellar dysplasia\"}","{\"db\":\"OMIM\",\"id\":\"147891\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PATELLA APLASIA, COXA VARA, AND TARSAL SYNOSTOSIS\"}","{\"db\":\"OMIM\",\"id\":\"168850\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PATELLA APLASIA, COXA VARA, AND TARSAL SYNOSTOSIS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Patella+aplasia%2C+coxa+vara%2C+tarsal+synostosis/5626\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Patella aplasia, coxa vara, tarsal synostosis\"}","{\"db\":\"OMIM\",\"id\":\"147891\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ICPPS\"}","{\"db\":\"OMIM\",\"id\":\"147891\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SPS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3030\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007841\",\"ref_field\":\"name\"}"],"name":"Coxopodopatellar syndrome","attribute_content":[],"type":"Disease","id":"3738"}
{"medgen_id":"C0265554","alternate_names":["Cleft hand","Lobster claw hand","Split hand foot malformation"],"keywords":[],"alternate_symbols":["SHFM"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100257\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100257\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cleft hand\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100257\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Lobster claw hand\"}","{\"db\":\"GeneTests\",\"id\":\"2427\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ectrodactyly/2464\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100257\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"81208006\",\"ref_field\":\"name\"}"],"name":"Ectrodactyly","attribute_content":[],"type":"Disease","id":"9488"}
{"medgen_id":"C0272340","alternate_names":["FITZGERALD TRAIT","Fitzgerald factor deficiency","Flaujeac factor deficiency","Kininogen deficiency","Reduced kininogen activity","Williams factor deficiency","Williams-Fitzgerald-Flaujeac factor deficiency"],"keywords":[],"alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004867\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005500\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005527\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005530\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005538\",\"type\":\"secondary\"}","{\"db\":\"OMIM\",\"id\":\"228960\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"228960\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FITZGERALD TRAIT\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005527\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fitzgerald factor deficiency\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005527\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Kininogen deficiency\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005527\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Reduced kininogen activity\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005527\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Williams factor deficiency\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005527\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Williams-Fitzgerald-Flaujeac factor deficiency\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Flaujeac+Factor+Deficiency/2875\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"27312002\",\"ref_field\":\"name\"}"],"name":"High molecular weight kininogen deficiency","attribute_content":[],"type":"Disease","id":"5252"}
{"medgen_id":"C0342418","alternate_names":["Hamartoma of the hypothalamus","Hypothalamic hamartoma","Hypothalamic hamartomas"],"keywords":["Hereditary cancer syndrome","Neoplasm"],"symbol":"PHLS","alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002444\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"241800\",\"type\":\"MIM\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002444\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hypothalamic hamartoma\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hypothalamic+hamartomas/3697\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"237714006\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"241800\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Hamartoma of hypothalamus","attribute_content":[],"type":"Disease","id":"2282"}
{"medgen_id":"C4522164","alternate_names":["HYPOHIDROSIS, ELECTROLYTE IMBALANCE, LACRIMAL GLAND DYSFUNCTION, ICHTHYOSIS, AND XEROSTOMIA"],"keywords":[],"symbol":"HELIX","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"617671\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"617671\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOHIDROSIS, ELECTROLYTE IMBALANCE, LACRIMAL GLAND DYSFUNCTION, ICHTHYOSIS, AND XEROSTOMIA\"}","{\"db\":\"OMIM\",\"id\":\"617579.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617579.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617579.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617671\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617671\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"HELIX SYNDROME","attribute_content":[],"type":"Disease","id":"38111"}
{"medgen_id":"C4479631","alternate_names":[],"keywords":[],"symbol":"NDMSBA","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0060502\"}","{\"db\":\"OMIM\",\"id\":\"617527\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"521426\"}","{\"db\":\"OMIM\",\"id\":\"603873.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603873.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603873.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603873.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603873.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617527\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617527\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"NEURODEVELOPMENTAL DISORDER WITH PROGRESSIVE MICROCEPHALY, SPASTICITY, AND BRAIN ANOMALIES","attribute_content":[],"type":"Disease","id":"37870"}
{"medgen_id":"CN272919","alternate_names":[],"keywords":[],"symbol":"WRWFFR","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"301041\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"301041\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Wieacker-Wolff syndrome, female-restricted","attribute_content":[],"type":"Disease","id":"43821"}
{"medgen_id":"C4310754","alternate_names":[],"keywords":[],"symbol":"MPD5","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"617030\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"617030\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Myopathy, distal, 5","attribute_content":[],"type":"Disease","id":"35761"}
{"medgen_id":"C3695272","alternate_names":[],"keywords":[],"alternate_symbols":[],"xrefs":[],"name":"Albinism, oculocutaneous, type VI","attribute_content":[],"type":"Disease","id":"18203"}
{"medgen_id":"CN236771","alternate_names":[],"keywords":[],"alternate_symbols":[],"xrefs":["{\"db\":\"Genetic Testing Lab, Ashok and Rita Patel Institute of Integrated Study and Research in Biotechnology and Allied Sciences\",\"id\":\"NS_11_030501\",\"ref_field\":\"name\"}"],"name":"Prednisolone response","attribute_content":[],"type":"DrugResponse","id":"35650"}
{"medgen_id":"C0443147","alternate_names":[],"keywords":[],"alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000006\",\"type\":\"primary\"}"],"name":"Autosomal dominant inheritance","attribute_content":["{\"Attribute\":{\"$\":\"MGG-2274\",\"@Type\":\"exclude from dictionary\"}}"],"type":"Disease","id":"33542"}
{"medgen_id":"C4225424","alternate_names":["Cataract, microphthalmia and nystagmus","OPTIC DISC ANOMALIES WITH RETINAL AND/OR MACULAR DYSTROPHY"],"keywords":[],"symbol":"ODRMD","alternate_symbols":["MCOPCT2"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008927\"}","{\"db\":\"OMIM\",\"id\":\"212550\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"435930\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cataract%2C+Microphthalmia+and+Nystagmus/1156\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cataract, microphthalmia and nystagmus\"}","{\"db\":\"OMIM\",\"id\":\"212550\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPTIC DISC ANOMALIES WITH RETINAL AND/OR MACULAR DYSTROPHY\"}","{\"db\":\"OMIM\",\"id\":\"606326.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPTIC DISC ANOMALIES WITH RETINAL AND/OR MACULAR DYSTROPHY\"}","{\"db\":\"OMIM\",\"id\":\"606326.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPTIC DISC ANOMALIES WITH RETINAL AND/OR MACULAR DYSTROPHY\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008927\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"microphthalmia\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"212550\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Colobomatous optic disc-macular atrophy-chorioretinopathy syndrome","attribute_content":[],"type":"Disease","public_definition":"Microphthalmia is an eye abnormality that arises before birth. In this condition, one or both eyeballs are abnormally small. In some affected individuals, the eyeball may appear to be completely missing; however, even in these cases some remaining eye tissue is generally present. Such severe microphthalmia should be distinguished from another condition called anophthalmia, in which no eyeball forms at all. However, the terms anophthalmia and severe microphthalmia are often used interchangeably. Microphthalmia may or may not result in significant vision loss.People with microphthalmia may also have a condition called coloboma. Colobomas are missing pieces of tissue in structures that form the eye. They may appear as notches or gaps in the colored part of the eye called the iris; the retina, which is the specialized light-sensitive tissue that lines the back of the eye; the blood vessel layer under the retina called the choroid; or in the optic nerves, which carry information from the eyes to the brain. Colobomas may be present in one or both eyes and, depending on their size and location, can affect a person's vision.People with microphthalmia may also have other eye abnormalities, including clouding of the lens of the eye (cataract) and a narrowed opening of the eye (narrowed palpebral fissure). Additionally, affected individuals may have an abnormality called microcornea, in which the clear front covering of the eye (cornea) is small and abnormally curved.Between one-third and one-half of affected individuals have microphthalmia as part of a syndrome that affects other organs and tissues in the body. These forms of the condition are described as syndromic. When microphthalmia occurs by itself, it is described as nonsyndromic or isolated.","id":"2794"}
{"medgen_id":"C4540232","alternate_names":["PLATELET ABNORMALITIES WITH EOSINOPHILIA AND IMMUNE-MEDIATED INFLAMMATORY DISEASE"],"keywords":[],"symbol":"IMD71","alternate_symbols":["PLTEID"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0060583\"}","{\"db\":\"OMIM\",\"id\":\"617718\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"617718\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PLATELET ABNORMALITIES WITH EOSINOPHILIA AND IMMUNE-MEDIATED INFLAMMATORY DISEASE\"}","{\"db\":\"OMIM\",\"id\":\"617718\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PLTEID\"}","{\"db\":\"OMIM\",\"id\":\"604223.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"604223.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"604223.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"604223.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"604223.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"604223.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"604223.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"604223.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"604223.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617718\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617718\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"IMMUNODEFICIENCY 71 WITH INFLAMMATORY DISEASE AND CONGENITAL THROMBOCYTOPENIA","attribute_content":[],"type":"Disease","id":"38314"}
{"medgen_id":"C0242647","alternate_names":["MALT LYMPHOMA, SOMATIC","MALT lymphoma"],"keywords":[],"alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"603517.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MALT LYMPHOMA, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"603517.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MALT LYMPHOMA, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"603517.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MALT LYMPHOMA, SOMATIC\"}","{\"db\":\"SNOMED CT\",\"id\":\"277622004\",\"ref_field\":\"name\"}"],"name":"Mucosa-associated lymphoma","attribute_content":[],"type":"Disease","id":"17630"}
{"medgen_id":"C0007194","alternate_names":[],"keywords":[],"alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001639\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0005045\"}","{\"db\":\"MeSH\",\"id\":\"D002312\"}","{\"db\":\"Orphanet\",\"id\":\"217569\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001639\",\"ref_field\":\"name\"}"],"name":"Hypertrophic cardiomyopathy","attribute_content":[],"type":"Disease","id":"22501"}
{"medgen_id":"C0809936","alternate_names":["BSG syndrome","Elsahy-Waters syndrome","Hypospadias, hypertelorism, upper lid coloboma, and mixed-type hearing loss"],"keywords":[],"symbol":"ESWS","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"211380\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1299\"}","{\"db\":\"Orphanet\",\"id\":\"157788\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Brachioskeletogenital+Syndrome/914\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"211380\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Brachioskeletogenital syndrome","attribute_content":[],"type":"Disease","id":"628"}
{"medgen_id":"C4693651","alternate_names":["OFDS XVIII","ORAL-FACIAL-DIGITAL SYNDROME, TYPE XVIII","OROFACIODIGITAL SYNDROME XVIII"],"keywords":[],"alternate_symbols":["OFD18"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0054770\"}","{\"db\":\"OMIM\",\"id\":\"617927\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"617927\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OFDS XVIII\"}","{\"db\":\"OMIM\",\"id\":\"617927\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ORAL-FACIAL-DIGITAL SYNDROME, TYPE XVIII\"}","{\"db\":\"OMIM\",\"id\":\"617927\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OROFACIODIGITAL SYNDROME XVIII\"}","{\"db\":\"OMIM\",\"id\":\"617927\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"OFD18\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0054770\",\"ref_field\":\"name\"}"],"name":"Orofaciodigital syndrome 18","attribute_content":[],"type":"Disease","id":"39750"}
{"medgen_id":"C4225310","alternate_names":["NEURODEVELOPMENTAL DISORDER WITH PROGRESSIVE MICROCEPHALY, SPASTICITY, AND BRAIN IMAGING ABNORMALITIES"],"keywords":[],"symbol":"NEDMISBA","alternate_symbols":["MCPH15"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014660\"}","{\"db\":\"OMIM\",\"id\":\"616486\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2512\"}","{\"db\":\"OMIM\",\"id\":\"616486\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURODEVELOPMENTAL DISORDER WITH PROGRESSIVE MICROCEPHALY, SPASTICITY, AND BRAIN IMAGING ABNORMALITIES\"}","{\"db\":\"OMIM\",\"id\":\"616486\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MCPH15\"}","{\"db\":\"OMIM\",\"id\":\"616486\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Primary autosomal recessive microcephaly 15","attribute_content":[],"type":"Disease","id":"33613"}
{"medgen_id":"C1862852","alternate_names":["ANKYLOSING SPONDYLITIS, SUSCEPTIBILITY TO","ANKYLOSING SPONDYLITIS, SUSCEPTIBILITY TO, 1","Ankylosing spondylitis 1","Disorder of joint of spine","SPONDYLOARTHROPATHY, SUSCEPTIBILITY TO, 1","Spondylarthropathies","spondylitis ankylosans"],"keywords":[],"symbol":"SPDA1","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"106300\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"825\"}","{\"db\":\"OMIM\",\"id\":\"106300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ANKYLOSING SPONDYLITIS, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"142830.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ANKYLOSING SPONDYLITIS, SUSCEPTIBILITY TO, 1\"}","{\"db\":\"SNOMED CT\",\"id\":\"372109003\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Disorder of joint of spine\"}","{\"db\":\"OMIM\",\"id\":\"106300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPONDYLOARTHROPATHY, SUSCEPTIBILITY TO, 1\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ankylosing+Spondylitis/482\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"9631008\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"106300\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Ankylosing spondylitis","attribute_content":[],"type":"Disease","id":"17370"}
{"medgen_id":"C1832648","alternate_names":[],"keywords":[],"alternate_symbols":["ADH"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"PS146200\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"2238\"}","{\"db\":\"Orphanet\",\"id\":\"2238\",\"ref_field\":\"name\"}"],"name":"Familial isolated hypoparathyroidism","attribute_content":[],"type":"Disease","id":"2273"}
{"disease_mechanism":"Fabry disease is due to inactivating mutations in the X-linked GLA gene resulting in deficiency of the enzyme Alpha Galactosidase-A.","content":"{\"Citation\":[{\"@Type\":\"general\",\"ID\":{\"$\":\"3009617\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301469\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1292\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"HFSA, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20610207\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"12735292\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Eng et al., 2006\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"16980809\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Salviati et al, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"2869001\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGentest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21934708\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AHA/ASA, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25355838\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23860966\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","medgen_id":"C0002986","alternate_names":["Alpha-galactosidase A deficiency","Anderson-Fabry disease","Angiokeratoma corporis diffusum","Angiokeratoma, diffuse","Ceramide trihexosidase deficiency","Ceramide trihexosidosis","Fabry syndrome","Fabry's disease","GLA deficiency","Hereditary dystopic lipidosis"],"keywords":[],"gard_id":"6400","alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010526\"}","{\"db\":\"OMIM\",\"id\":\"301500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"324\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Angiokeratoma corporis diffusum\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fabry+Disease/2690\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"SNOMED CT\",\"id\":\"16652001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500007\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6400\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"fabry-disease\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1292\",\"ref_field\":\"public_definition\"}"],"name":"Fabry disease","attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528536\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556501\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000514924\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520414\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528516\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000551442\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000325415\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000512526\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528276\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528500\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000505068\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507480\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000246735\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000260631\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520063\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520447\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528528\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000552214\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556520\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000558532\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507942\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000522527\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000568367\"}]}"],"type":"Disease","public_definition":"Fabry disease results from deficient activity of the enzyme alpha-galactosidase A (a-Gal A) and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The classic form, occurring in males with less than 1% a-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, they may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype. In contrast, males with greater than 1% a-Gal A activity may have: (1) a cardiac variant phenotype that usually presents in the sixth to eighth decade with left ventricular hypertrophy, cardiomyopathy and arrhythmia, and proteinuria, but without ESRD; or (2) a renal variant phenotype, associated with ESRD but without the skin lesions or pain; or (3) cerebrovascular disease presenting as stroke or transient ischemic attack.","id":"1790"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301720\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1727\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"WGO, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23314668\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"BSG, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24917550\",\"@Source\":\"PubMed\"}}]}","medgen_id":"C0007570","alternate_names":["Celiac sprue","Gluten-sensitive enteropathy"],"keywords":["Neoplasm"],"gard_id":"11998","symbol":"CD","alternate_symbols":["CELIAC1"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002608\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0005130\"}","{\"db\":\"OMIM\",\"id\":\"PS212750\",\"type\":\"Phenotypic series\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002608\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Celiac sprue\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500745\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CELIAC1\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"11998\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Celiac+Disease/1186\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002608\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"PS212750\",\"type\":\"Phenotypic series\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"396331005\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1727\",\"ref_field\":\"public_definition\"}"],"name":"Celiac disease","attribute_content":[],"type":"Disease","public_definition":"Celiac disease is a systemic autoimmune disease that can be associated with gastrointestinal findings (diarrhea, malabsorption, abdominal pain and distension, bloating, vomiting, and weight loss) and/or highly variable non-gastrointestinal findings (dermatitis herpetiformis, chronic fatigue, joint pain/inflammation, iron deficiency anemia, migraines, depression, attention-deficit disorder, epilepsy, osteoporosis/osteopenia, infertility and/or recurrent fetal loss, vitamin deficiencies, short stature, failure to thrive, delayed puberty, dental enamel defects, and autoimmune disorders). Classic celiac disease, characterized by mild to severe gastrointestinal symptoms, is less common than non-classic celiac disease, characterized by absence of gastrointestinal symptoms.","id":"4758"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301328\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1149\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3111012\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"3039492\",\"@Source\":\"pmc\"}}]}","medgen_id":"C0023374","alternate_names":["Hypoxanthine guanine phospho-ribosyltransferase 1 deficiency","Hypoxanthine guanine phosphoribosyltransferase deficiency"],"keywords":[],"symbol":"LNS","alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"300322\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"510\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Lesch+Nyhan+syndrome/4181\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"lesch-nyhan-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"10406007\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1149\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"300322\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Lesch-Nyhan syndrome","attribute_content":[],"type":"Disease","public_definition":"HPRT1 disorders, caused by deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGprt), are typically associated with clinical evidence for overproduction of uric acid (hyperuricemia, nephrolithiasis, and/or gouty arthritis) and varying degrees of neurologic and/or behavioral problems. Historically, three phenotypes were identified in the spectrum of HPRT1 disorders: Lesch-Nyhan disease (LND) at the most severe end with motor dysfunction resembling severe cerebral palsy, intellectual disability, and self-injurious behavior; HPRT1-related neurologic dysfunction (HND) in the intermediate range with similar but fewer severe neurologic findings than LND and no self-injurious behavior; and HPRT1-related hyperuricemia (HRH) at the mild end without overt neurologic deficits. It is now recognized that these neurobehavioral phenotypes cluster along a continuum from severe to mild.","id":"5397"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301479\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1302\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2012\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22237449\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31021589\",\"@Source\":\"PubMed\"},{\"$\":\"NBK540447\",\"@Source\":\"BookShelf\"}]}]}","medgen_id":"C2020284","alternate_names":["Arthroophthalmopathy, hereditary progressive","Stickler syndrome type 1","Stickler syndrome, membranous vitreous type","Stickler syndrome, vitreous type 1"],"keywords":[],"gard_id":"5018","symbol":"STL1","alternate_symbols":["AOM","COL11A1"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007160\"}","{\"db\":\"OMIM\",\"id\":\"108300\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"828\"}","{\"db\":\"Orphanet\",\"id\":\"90653\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Stickler+syndrome+type+1/6878\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Stickler syndrome type 1\"}","{\"db\":\"OMIM\",\"id\":\"108300\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"AOM\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5018\",\"ref_field\":\"gard_id\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1302\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"108300\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"type":"Disease","public_definition":"Stickler syndrome is a connective tissue disorder that can include ocular findings of myopia, cataract, and retinal detachment; hearing loss that is both conductive and sensorineural; midfacial underdevelopment and cleft palate (either alone or as part of the Robin sequence); and mild spondyloepiphyseal dysplasia and/or precocious arthritis. Variable phenotypic expression of Stickler syndrome occurs both within and among families; interfamilial variability is in part explained by locus and allelic heterogeneity.","id":"3852"}
{"content":"{\"Citation\":{\"@Abbrev\":\"Langer et al., 2012\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22947299\",\"@Source\":\"PubMed\"}}}","medgen_id":"C0025517","alternate_names":[],"keywords":[],"symbol":"Metabolic","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0005066\"}","{\"db\":\"CSER _CC_NCGL, University of Washington\",\"id\":\"UWMG_9636043\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"75934005\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000591270\",\"ref_field\":\"symbol\"}"],"name":"Metabolic disease","attribute_content":[],"type":"Disease","id":"32361"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301328\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1149\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C0268117","alternate_names":["GOUT, HPRT-RELATED","HPRT DEFICIENCY, PARTIAL","HPRT-related hyperuricemia","HPRT1 DEFICIENCY, PARTIAL","HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY, PARTIAL","KELLEY-SEEGMILLER SYNDROME"],"keywords":[],"symbol":"HRH","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010299\"}","{\"db\":\"OMIM\",\"id\":\"300323\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"79233\"}","{\"db\":\"OMIM\",\"id\":\"300323\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GOUT, HPRT-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"308000.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GOUT, HPRT-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"308000.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GOUT, HPRT-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"308000.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GOUT, HPRT-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"308000.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GOUT, HPRT-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"308000.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GOUT, HPRT-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"308000.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GOUT, HPRT-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"308000.0034\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GOUT, HPRT-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"308000.0039\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GOUT, HPRT-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"308000.0048\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GOUT, HPRT-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"308000.0054\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GOUT, HPRT-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"308000.0056\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GOUT, HPRT-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"308000.0060\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GOUT, HPRT-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"300323\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HPRT DEFICIENCY, PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"308000.0049\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HPRT DEFICIENCY, PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"308000.0050\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HPRT DEFICIENCY, PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"308000.0051\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HPRT DEFICIENCY, PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"308000.0059\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HPRT DEFICIENCY, PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"300323\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HPRT1 DEFICIENCY, PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"300323\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY, PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"300323\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"KELLEY-SEEGMILLER SYNDROME\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Partial+hypoxanthine-guanine+phosphoribosyltransferase+deficiency/9096\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"238007004\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1149\",\"ref_field\":\"public_definition\"}"],"name":"Partial hypoxanthine-guanine phosphoribosyltransferase deficiency","attribute_content":[],"type":"Disease","public_definition":"HPRT1 disorders, caused by deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGprt), are typically associated with clinical evidence for overproduction of uric acid (hyperuricemia, nephrolithiasis, and/or gouty arthritis) and varying degrees of neurologic and/or behavioral problems. Historically, three phenotypes were identified in the spectrum of HPRT1 disorders: Lesch-Nyhan disease (LND) at the most severe end with motor dysfunction resembling severe cerebral palsy, intellectual disability, and self-injurious behavior; HPRT1-related neurologic dysfunction (HND) in the intermediate range with similar but fewer severe neurologic findings than LND and no self-injurious behavior; and HPRT1-related hyperuricemia (HRH) at the mild end without overt neurologic deficits. It is now recognized that these neurobehavioral phenotypes cluster along a continuum from severe to mild.","id":"5209"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301394\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1215\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C0265309","alternate_names":["Dyschondrosteosis","LÃ©ri-Weill dyschondrosteosis"],"keywords":[],"gard_id":"3224","symbol":"LWD","alternate_symbols":["DCO"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007481\"}","{\"db\":\"OMIM\",\"id\":\"127300\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"240\"}","{\"db\":\"OMIM\",\"id\":\"127300\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DCO\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3224\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007481\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1215\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"127300\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Leri-Weill dyschondrosteosis","attribute_content":[],"type":"Disease","public_definition":"The phenotypic spectrum of SHOX deficiency disorders, caused by haploinsufficiency of the short stature homeobox-containing gene (SHOX), ranges from Leri-Weill dyschondrosteosis (LWD) at the severe end of the spectrum to nonspecific short stature at the mild end of the spectrum. In adults with SHOX deficiency, the proportion of LWD versus short stature without features of LWD is not well defined. In LWD the classic clinical triad is short stature, mesomelia, and Madelung deformity. Mesomelia, in which the middle portion of a limb is shortened in relation to the proximal portion, can be evident first in school-aged children and increases with age in frequency and severity. Madelung deformity (abnormal alignment of the radius, ulna, and carpal bones at the wrist) typically develops in mid-to-late childhood and is more common and severe in females. The phenotype of short stature caused by SHOX deficiency in the absence of mesomelia and Madelung deformity (called SHOX-deficient short stature in this GeneReview) is highly variable, even within the same family.","id":"2677"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301413\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1235\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C1851413","alternate_names":["EXOSTOSES, MULTIPLE, TYPE II"],"keywords":["Neoplasm"],"gard_id":"2205","symbol":"EXT2","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007586\"}","{\"db\":\"OMIM\",\"id\":\"133701\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"321\"}","{\"db\":\"OMIM\",\"id\":\"133701\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EXOSTOSES, MULTIPLE, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"608210.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EXOSTOSES, MULTIPLE, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"608210.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EXOSTOSES, MULTIPLE, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"608210.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EXOSTOSES, MULTIPLE, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"608210.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EXOSTOSES, MULTIPLE, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"608210.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EXOSTOSES, MULTIPLE, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"608210.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EXOSTOSES, MULTIPLE, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"608210.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EXOSTOSES, MULTIPLE, TYPE II\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2205\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Exostoses%2C+Multiple%2C+Type+2/2676\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1235\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"133701\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Multiple exostoses type 2","attribute_content":[],"type":"Disease","public_definition":"Hereditary multiple osteochondromas (HMO), previously called hereditary multiple exostoses (HME), is characterized by growths of multiple osteochondromas, benign cartilage-capped bone tumors that grow outward from the metaphyses of long bones. Osteochondromas can be associated with a reduction in skeletal growth, bony deformity, restricted joint motion, shortened stature, premature osteoarthrosis, and compression of peripheral nerves. The median age of diagnosis is three years; nearly all affected individuals are diagnosed by age 12 years. The risk for malignant degeneration to osteochondrosarcoma increases with age, although the lifetime risk for malignant degeneration is low (~2%-5%).","id":"5054"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301413\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1235\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C0015306","alternate_names":["DIAPHYSEAL ACLASIS","MULTIPLE CARTILAGINOUS EXOSTOSES","MULTIPLE OSTEOCHONDROMAS","Multiple exostoses","OSTEOCHONDROMATOSIS"],"keywords":["Neoplasm"],"symbol":"EXT","alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002762\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"133700\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"321\"}","{\"db\":\"OMIM\",\"id\":\"133700\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIAPHYSEAL ACLASIS\"}","{\"db\":\"OMIM\",\"id\":\"133700\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE CARTILAGINOUS EXOSTOSES\"}","{\"db\":\"OMIM\",\"id\":\"133700\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE OSTEOCHONDROMAS\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002762\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Multiple exostoses\"}","{\"db\":\"OMIM\",\"id\":\"133700\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOCHONDROMATOSIS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Multiple+congenital+exostosis/8916\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"254044004\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1235\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"133700\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Multiple congenital exostosis","attribute_content":[],"type":"Disease","public_definition":"The disorder hereditary multiple osteochondromas (HMO), previously called hereditary multiple exostoses (HME), is characterized by growths of multiple osteochondromas (benign cartilage-capped bone tumors that grow outward from the metaphyses of long bones). Osteochondromas can be associated with a reduction in skeletal growth, bony deformity, restricted joint motion, shortened stature, premature osteoarthrosis, and compression of peripheral nerves. The median age of diagnosis is three years; nearly all affected individuals are diagnosed by age 12 years. The risk for malignant degeneration to osteochondrosarcoma increases with age, although the lifetime risk of malignant degeneration is low (~1%).","id":"5053"}
{"disease_mechanism":"Affects gamma-sarcoglycan and also disrupts the integrity of the entire sarcoglycan complex.","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301582\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1408\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C1832525","alternate_names":["Limb-girdle muscular dystrophy, type 2F","MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 6","Muscular dystrophy limb-girdle with delta-sarcoglyan deficiency"],"keywords":[],"gard_id":"8573","symbol":"LGMD2F","alternate_symbols":["LGMDR6"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011028\"}","{\"db\":\"OMIM\",\"id\":\"601287\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"219\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Limb-girdle+muscular+dystrophy%2C+type+2F/4241\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Limb-girdle muscular dystrophy, type 2F\"}","{\"db\":\"OMIM\",\"id\":\"601287\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 6\"}","{\"db\":\"OMIM\",\"id\":\"601411.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 6\"}","{\"db\":\"OMIM\",\"id\":\"601411.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 6\"}","{\"db\":\"OMIM\",\"id\":\"601411.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 6\"}","{\"db\":\"OMIM\",\"id\":\"601411.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 6\"}","{\"db\":\"OMIM\",\"id\":\"601411.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 6\"}","{\"db\":\"OMIM\",\"id\":\"601287\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LGMDR6\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509010\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8573\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011028\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"limb-girdle-muscular-dystrophy\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"601287\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Autosomal recessive limb-girdle muscular dystrophy type 2F","attribute_content":[],"type":"Disease","public_definition":"Limb-girdle muscular dystrophy is a term for a group of diseases that cause weakness and wasting of the muscles in the arms and legs. The muscles most affected are those closest to the body (proximal muscles), specifically the muscles of the shoulders, upper arms, pelvic area, and thighs.The severity, age of onset, and features of limb-girdle muscle dystrophy vary among the many subtypes of this condition and may be inconsistent even within the same family. Signs and symptoms may first appear at any age and generally worsen with time, although in some cases they remain mild.In the early stages of limb-girdle muscular dystrophy, affected individuals may have an unusual walking gait, such as waddling or walking on the balls of their feet, and may also have difficulty running. They may need to use their arms to press themselves up from a squatting position because of their weak thigh muscles. As the condition progresses, people with limb-girdle muscular dystrophy may eventually require wheelchair assistance.Muscle wasting may cause changes in posture or in the appearance of the shoulder, back, and arm. In particular, weak shoulder muscles tend to make the shoulder blades (scapulae) \"stick out\" from the back, a sign known as scapular winging. Affected individuals may also have an abnormally curved lower back (lordosis) or a spine that curves to the side (scoliosis). Some develop joint stiffness (contractures) that can restrict movement in their hips, knees, ankles, or elbows. Overgrowth (hypertrophy) of the calf muscles occurs in some people with limb-girdle muscular dystrophy.Weakening of the heart muscle (cardiomyopathy) occurs in some forms of limb-girdle muscular dystrophy. Some affected individuals experience mild to severe breathing problems related to the weakness of muscles needed for breathing. In some cases, the breathing problems are severe enough that affected individuals need to use a machine to help them breathe (mechanical ventilation).Intelligence is generally unaffected in limb-girdle muscular dystrophy; however, developmental delay and intellectual disability have been reported in rare forms of the disorder.","id":"5572"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301617\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1444\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C1863728","alternate_names":[],"keywords":[],"gard_id":"9929","symbol":"FHL4","alternate_symbols":["HLH4","HPLH4"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011336\"}","{\"db\":\"OMIM\",\"id\":\"603552\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"540\"}","{\"db\":\"OMIM\",\"id\":\"603552\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HLH4\"}","{\"db\":\"OMIM\",\"id\":\"603552\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HPLH4\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9929\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011336\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603552\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Familial hemophagocytic lymphohistiocytosis 4","attribute_content":[],"type":"Disease","id":"5240"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301537\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1363\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"3061994\",\"@Source\":\"pmc\"}}]}","medgen_id":"C1859564","alternate_names":[],"keywords":[],"gard_id":"822","symbol":"BBS3","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010832\"}","{\"db\":\"OMIM\",\"id\":\"600151\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"110\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"822\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Bardet-Biedl+Syndrome+3/729\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"600151\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Bardet-Biedl syndrome 3","attribute_content":[],"type":"Disease","id":"8915"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301537\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1363\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"3061994\",\"@Source\":\"pmc\"}}]}","medgen_id":"C2936863","alternate_names":[],"keywords":[],"gard_id":"821","symbol":"BBS2","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014432\"}","{\"db\":\"OMIM\",\"id\":\"615981\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"110\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"821\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Bardet-Biedl+Syndrome+2/728\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"615981\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Bardet-Biedl syndrome 2","attribute_content":[],"type":"Disease","id":"6439"}
{"disease_mechanism":"loss of function","medgen_id":"C1333990","alternate_names":["Colorectal cancer, hereditary nonpolyposis"],"keywords":[],"symbol":"HNPCC","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0018630\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568362\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568365\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"lynch-syndrome\",\"ref_field\":\"public_definition\"}"],"name":"Hereditary nonpolyposis colon cancer","attribute_content":[],"type":"Disease","public_definition":"Lynch syndrome, often called hereditary nonpolyposis colorectal cancer (HNPCC), is an inherited disorder that increases the risk of many types of cancer, particularly cancers of the colon (large intestine) and rectum, which are collectively referred to as colorectal cancer. People with Lynch syndrome also have an increased risk of cancers of the stomach, small intestine, liver, gallbladder ducts, urinary tract, brain, and skin. Additionally, women with this disorder have a high risk of cancer of the ovaries and lining of the uterus (endometrial cancer). Women with Lynch syndrome have a higher overall risk of developing cancer than men with the condition because of these cancers of the female reproductive system. Individuals with Lynch syndrome typically develop cancer in their forties or fifties.People with Lynch syndrome may occasionally have noncancerous (benign) growths in the colon, called colon polyps. In individuals with this disorder, colon polyps occur at a younger age but not in greater numbers than they do in the general population.","disease_mechanism_id":"273","id":"53477"}
{"disease_mechanism":"loss of function","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301677\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1504\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"USPSTF, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"2267416\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21915151\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24385074\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2014\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"3918542\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"Camp et al., 2014\",\"@Type\":\"Suggested Reading\",\"ID\":{\"$\":\"24667081\",\"@Source\":\"PubMed\"}}]}","medgen_id":"C0751434","alternate_names":["Classic phenylketonuria","Folling disease","Oligophrenia phenylpyruvica","Phenylketonurias"],"keywords":[],"symbol":"PKU","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009861\"}","{\"db\":\"OMIM\",\"id\":\"261600\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"716\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000260641\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000330994\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000505064\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000505124\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506557\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507953\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522527\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529111\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000560957\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Phenylketonuria/5714\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"154735006\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1504\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"261600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Phenylketonuria","attribute_content":[],"type":"Disease","public_definition":"Phenylalanine hydroxylase (PAH) deficiency results in intolerance to the dietary intake of the essential amino acid phenylalanine and produces a spectrum of disorders. The risk of adverse outcome varies based on the degree of PAH deficiency. Without effective therapy, most individuals with severe PAH deficiency, known as classic PKU, develop profound and irreversible intellectual disability. Affected individuals on an unrestricted diet who have phenylalanine levels above normal but below 1,200 Âµmol/L (20 mg/dL) are at much lower risk for impaired cognitive development in the absence of treatment.","disease_mechanism_id":"273","id":"3795"}
{"disease_mechanism":"loss of function","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20945555\",\"@Source\":\"PubMed\"},{\"$\":\"NBK47312\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C1969623","alternate_names":["Neurofibromatosis type 1 like syndrome"],"keywords":[],"gard_id":"10714","symbol":"LGSS","alternate_symbols":["NFLS","SPRED1"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012669\"}","{\"db\":\"OMIM\",\"id\":\"611431\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"137605\"}","{\"db\":\"OMIM\",\"id\":\"611431\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"NFLS\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500881\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501087\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506067\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509019\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509021\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511089\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514608\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520039\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521399\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522322\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528461\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551628\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551630\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000561717\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000562237\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000562238\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000562242\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568134\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568167\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569525\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10714\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Legius+syndrome/4153\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"legius-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK47312\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"611431\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Legius syndrome","attribute_content":[],"type":"Disease","public_definition":"Legius syndrome is characterized by multiple cafÃ© au lait macules without neurofibromas or other tumor manifestations of neurofibromatosis type 1 (NF1). Additional clinical manifestations reported commonly include intertriginous freckling, lipomas, macrocephaly, and learning disabilities / attention-deficit/hyperactivity disorder (ADHD) / developmental delays. Current knowledge of the natural history of Legius syndrome is based on the clinical manifestations of fewer than 300 individuals with a molecularly confirmed diagnosis; better delineation of the clinical manifestations and natural history of Legius syndrome will likely occur as more affected individuals are identified.","disease_mechanism_id":"273","id":"5389"}
{"disease_mechanism":"loss of function","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"29792621\",\"@Source\":\"PubMed\"},{\"$\":\"NBK500456\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C1841962","alternate_names":["Diabetes mellitus MODY type 2","MODY glucokinase-related","MODY type 2"],"keywords":[],"gard_id":"10657","symbol":"MODY2","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007453\"}","{\"db\":\"OMIM\",\"id\":\"125851\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"552\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512295\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512817\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552325\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552544\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556820\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556824\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000557910\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558434\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000559250\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568234\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000570044\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10657\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"maturity-onset-diabetes-of-the-young\",\"ref_field\":\"ghr_links\"}","{\"db\":\"OMIM\",\"id\":\"125851\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Maturity-onset diabetes of the young, type 2","attribute_content":[],"type":"Disease","disease_mechanism_id":"273","id":"5458","ghr_links":"maturity-onset diabetes of the young"}
{"disease_mechanism":"loss of function","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"29792621\",\"@Source\":\"PubMed\"},{\"$\":\"NBK500456\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C1838100","alternate_names":["Diabetes mellitus MODY type 3","MODY  type 3","MODY hepatocyte nuclear factor-1-alpha related","MODY, type III"],"keywords":[],"gard_id":"10658","symbol":"MODY3","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010894\"}","{\"db\":\"OMIM\",\"id\":\"600496\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"552\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000327171\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509011\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512295\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512817\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522248\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552325\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552546\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552549\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556820\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000557910\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558434\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000559250\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000570044\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10658\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"maturity-onset-diabetes-of-the-young\",\"ref_field\":\"ghr_links\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"maturity-onset-diabetes-of-the-young\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"600496\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Maturity-onset diabetes of the young, type 3","attribute_content":[],"type":"Disease","public_definition":"Maturity-onset diabetes of the young (MODY) is a group of several conditions characterized by abnormally high blood sugar levels. These forms of diabetes typically begin before age 30, although they can occur later in life. In MODY, elevated blood sugar arises from reduced production of insulin, which is a hormone produced in the pancreas that helps regulate blood sugar levels. Specifically, insulin controls how much glucose (a type of sugar) is passed from the blood into cells, where it is used as an energy source.The different types of MODY are distinguished by their genetic causes. The most common types are HNF1A-MODY (also known as MODY3), accounting for 50 to 70 percent of cases, and GCK-MODY (MODY2), accounting for 30 to 50 percent of cases. Less frequent types include HNF4A-MODY (MODY1) and renal cysts and diabetes (RCAD) syndrome (also known as HNF1B-MODY or MODY5), which each account for 5 to 10 percent of cases. At least ten other types have been identified, and these are very rare.HNF1A-MODY and HNF4A-MODY have similar signs and symptoms that develop slowly over time. Early signs and symptoms in these types are caused by high blood sugar and may include frequent urination (polyuria), excessive thirst (polydipsia), fatigue, blurred vision, weight loss, and recurrent skin infections. Over time uncontrolled high blood sugar can damage small blood vessels in the eyes and kidneys. Damage to the light-sensitive tissue at the back of the eye (the retina) causes a condition known as diabetic retinopathy that can lead to vision loss and eventual blindness. Kidney damage (diabetic nephropathy) can lead to kidney failure and end-stage renal disease (ESRD). While these two types of MODY are very similar, certain features are particular to each type. For example, babies with HNF4A-MODY tend to weigh more than average or have abnormally low blood sugar at birth, even though other signs of the condition do not occur until childhood or young adulthood. People with HNF1A-MODY have a higher-than-average risk of developing noncancerous (benign) liver tumors known as hepatocellular adenomas.GCK-MODY is a very mild type of the condition. People with this type have slightly elevated blood sugar levels, particularly in the morning before eating (fasting blood sugar). However, affected individuals often have no symptoms related to the disorder, and diabetes-related complications are extremely rare.RCAD is associated with a combination of diabetes and kidney or urinary tract abnormalities (unrelated to the elevated blood sugar), most commonly fluid-filled sacs (cysts) in the kidneys. However, the signs and symptoms are variable, even within families, and not everyone with RCAD has both features. Affected individuals may have other features unrelated to diabetes, such as abnormalities of the pancreas or liver or a form of arthritis called gout.","disease_mechanism_id":"273","id":"2650","ghr_links":"maturity-onset diabetes of the young"}
{"disease_mechanism":"loss of function","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"29792621\",\"@Source\":\"PubMed\"},{\"$\":\"NBK500456\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C1852093","alternate_names":["Diabetes mellitus MODY type 1","HNF4A-Related Maturity-Onset Diabetes of the Young Type 1","MILD JUVENILE DIABETES MELLITUS","MODY HNF4A related","MODY type 1","MODY, type I"],"keywords":[],"gard_id":"3418","symbol":"MODY1","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007452\"}","{\"db\":\"OMIM\",\"id\":\"125850\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"552\"}","{\"db\":\"OMIM\",\"id\":\"125850\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MILD JUVENILE DIABETES MELLITUS\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000330522\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512295\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512817\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552325\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552547\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556820\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000557910\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558434\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000559250\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569090\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000570044\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3418\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"maturity-onset-diabetes-of-the-young\",\"ref_field\":\"ghr_links\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"maturity-onset-diabetes-of-the-young\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"125850\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Maturity-onset diabetes of the young, type 1","attribute_content":[],"type":"Disease","public_definition":"Maturity-onset diabetes of the young (MODY) is a group of several conditions characterized by abnormally high blood sugar levels. These forms of diabetes typically begin before age 30, although they can occur later in life. In MODY, elevated blood sugar arises from reduced production of insulin, which is a hormone produced in the pancreas that helps regulate blood sugar levels. Specifically, insulin controls how much glucose (a type of sugar) is passed from the blood into cells, where it is used as an energy source.The different types of MODY are distinguished by their genetic causes. The most common types are HNF1A-MODY (also known as MODY3), accounting for 50 to 70 percent of cases, and GCK-MODY (MODY2), accounting for 30 to 50 percent of cases. Less frequent types include HNF4A-MODY (MODY1) and renal cysts and diabetes (RCAD) syndrome (also known as HNF1B-MODY or MODY5), which each account for 5 to 10 percent of cases. At least ten other types have been identified, and these are very rare.HNF1A-MODY and HNF4A-MODY have similar signs and symptoms that develop slowly over time. Early signs and symptoms in these types are caused by high blood sugar and may include frequent urination (polyuria), excessive thirst (polydipsia), fatigue, blurred vision, weight loss, and recurrent skin infections. Over time uncontrolled high blood sugar can damage small blood vessels in the eyes and kidneys. Damage to the light-sensitive tissue at the back of the eye (the retina) causes a condition known as diabetic retinopathy that can lead to vision loss and eventual blindness. Kidney damage (diabetic nephropathy) can lead to kidney failure and end-stage renal disease (ESRD). While these two types of MODY are very similar, certain features are particular to each type. For example, babies with HNF4A-MODY tend to weigh more than average or have abnormally low blood sugar at birth, even though other signs of the condition do not occur until childhood or young adulthood. People with HNF1A-MODY have a higher-than-average risk of developing noncancerous (benign) liver tumors known as hepatocellular adenomas.GCK-MODY is a very mild type of the condition. People with this type have slightly elevated blood sugar levels, particularly in the morning before eating (fasting blood sugar). However, affected individuals often have no symptoms related to the disorder, and diabetes-related complications are extremely rare.RCAD is associated with a combination of diabetes and kidney or urinary tract abnormalities (unrelated to the elevated blood sugar), most commonly fluid-filled sacs (cysts) in the kidneys. However, the signs and symptoms are variable, even within families, and not everyone with RCAD has both features. Affected individuals may have other features unrelated to diabetes, such as abnormalities of the pancreas or liver or a form of arthritis called gout.","disease_mechanism_id":"273","id":"2649","ghr_links":"maturity-onset diabetes of the young"}
{"disease_mechanism":"loss of function","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301495\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1319\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GMDI/SERC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24881969\",\"@Source\":\"PubMed\"}}]}","medgen_id":"C0024776","alternate_names":["Branched chain ketoaciduria","Branched-chain alpha-keto acid dehydrogenase deficiency","Keto acid decarboxylase deficiency"],"keywords":[],"gard_id":"3228","symbol":"MSUD","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009563\"}","{\"db\":\"MeSH\",\"id\":\"D008375\"}","{\"db\":\"OMIM\",\"id\":\"248600\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"PS248600\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"511\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000505096\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000505125\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519087\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521391\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522317\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522527\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528448\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528449\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529111\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000561777\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000570054\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3228\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Maple+syrup+urine+disease/4453\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"PS248600\",\"type\":\"Phenotypic series\",\"ref_field\":\"name\"}","{\"db\":\"Orphanet\",\"id\":\"511\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"27718001\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1319\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"248600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Maple syrup urine disease","attribute_content":[],"type":"Disease","public_definition":"Maple syrup urine disease (MSUD) is categorized as classic (severe), intermediate, or intermittent. Neonates with classic MSUD are born asymptomatic but without treatment follow a predictable course: 12â24 hours: Elevated concentrations of branched-chain amino acids (BCAAs; leucine, isoleucine, and valine) and alloisoleucine, as well as a generalized disturbance of amino acid concentration ratios, are present in blood and the maple syrup odor can be detected in cerumen; Two to three days: Early and nonspecific signs of metabolic intoxication (i.e., irritability, hypersomnolence, anorexia) are accompanied by the presence of branched-chain alpha-ketoacids, acetoacetate, and beta-hydroxybutyrate in urine; Four to six days: Worsening encephalopathy manifests as lethargy, apnea, opisthotonos, and reflexive \"fencing\" or \"bicycling\" movements as the sweet maple syrup odor becomes apparent in urine; Seven to ten days: Severe intoxication culminates in critical cerebral edema, coma, and central respiratory failure. Individuals with intermediate MSUD have partial branched-chain alpha-ketoacid dehydrogenase deficiency that manifests only intermittently or responds to dietary thiamine therapy; these individuals can experience severe metabolic intoxication and encephalopathy in the face of sufficient catabolic stress. In the era of newborn screening (NBS), the prompt initiation of treatment of asymptomatic infants detected by NBS means that most individuals who would have developed neonatal manifestations of MSUD remain asymptomatic with continued treatment compliance.","disease_mechanism_id":"273","id":"2822"}
{"disease_mechanism":"gain of function","content":"{\"Citation\":[{\"@Abbrev\":\"Biesecker et al., 1998\",\"@Type\":\"Suggested Reading\",\"ID\":{\"$\":\"10360391\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Turner et al., 2004\",\"@Type\":\"Suggested Reading\",\"ID\":{\"$\":\"15372514\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Lindhurst et al., 2011\",\"@Type\":\"Suggested Reading\",\"ID\":{\"$\":\"21793738\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"22876373\",\"@Source\":\"PubMed\"},{\"$\":\"NBK99495\",\"@Source\":\"BookShelf\"}]}]}","medgen_id":"C0085261","alternate_names":["Elattoproteus syndrome","Gigantism, partial, of hands and feet, nevi, hemihypertrophy, and macrocephaly","Hemihypertrophy and macrocephaly","Macrocephaly mesodermal hamartoma spectrum","PROTEUS SYNDROME, SOMATIC","Partial gigantism of hands and feet, nevi, hemihypertrophy, macrocephaly"],"keywords":["Hereditary cancer syndrome","Neoplasm"],"gard_id":"7475","alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008318\"}","{\"db\":\"OMIM\",\"id\":\"176920\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"744\"}","{\"db\":\"OMIM\",\"id\":\"164730.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PROTEUS SYNDROME, SOMATIC\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508960\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515534\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515803\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520081\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528059\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528379\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528912\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7475\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Proteus+syndrome/6005\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"proteus-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"23150001\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK99495\",\"ref_field\":\"public_definition\"}"],"name":"Proteus syndrome","attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000551654\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000552540\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000570020\"}]}"],"type":"Disease","public_definition":"Proteus syndrome is characterized by progressive segmental or patchy overgrowth most commonly affecting the skeleton, skin, adipose, and central nervous systems. In most individuals Proteus syndrome has modest or no manifestations at birth, develops and progresses rapidly beginning in the toddler period, and relentlessly progresses through childhood, causing severe overgrowth and disfigurement. It is associated with a range of tumors, pulmonary complications, and a striking predisposition to deep vein thrombosis and pulmonary embolism.","disease_mechanism_id":"274","id":"4046"}
